Document is current
Any future updates will be listed below
-
Authors
Nguyen, Diep Thi Ngoc
Hughes, Suzanne
Egger, Sam
LaMontagne, D. Scott
Simms, Kate
Castle, Phillip E.
Canfell, Karen
- License Information
-
More Information
Article History
Received: 7 June 2018
Accepted: 12 July 2019
First Online: 11 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: KC is co-PI of an investigator-initiated trial of cytology and primary HPV screening in Australia (‘Compass’) (NCT02328872), which is conducted and funded by the Victorian Cytology Service (VCS), a government-funded health promotion charity. The VCS have received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana Inc. USA. KC is also a PI on Compass in New Zealand, (‘Compass NZ’) (ACTRN12614000714684) which is conducted and funded by Diagnostic Medlab (DML), now Auckland District Health Board. DML received an equipment and a funding contribution for the Compass trial from Roche Molecular Systems. However, neither KC nor her institution on her behalf (Cancer Council NSW) receive direct or indirect funding from industry for these trials or any other project.PC has received commercial HPV tests for research at a reduced or no cost from Roche, BD, Cepheid, and Arbor Vita Corporation.
